4.43
+0.43(+10.75%)
Currency In USD
| Previous Close | 4 |
| Open | 4.01 |
| Day High | 4.44 |
| Day Low | 4.01 |
| 52-Week High | 16.94 |
| 52-Week Low | 1.52 |
| Volume | 24,342 |
| Average Volume | 30,745 |
| Market Cap | 115.12M |
| PE | -0.37 |
| EPS | -12.03 |
| Moving Average 50 Days | 3.54 |
| Moving Average 200 Days | 3.23 |
| Change | 0.43 |
If you invested $1000 in Senti Biosciences, Inc. (SNTI) since IPO date, it would be worth $44.39 as of April 24, 2025 at a share price of $4.43. Whereas If you bought $1000 worth of Senti Biosciences, Inc. (SNTI) shares 3 years ago, it would be worth $44.77 as of April 24, 2025 at a share price of $4.43.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Senti Bio Participates in a Virtual Investor KOL Connect Segment
GlobeNewswire Inc.
Apr 21, 2025 1:05 PM GMT
Moderated discussion with Stephen Strickland, MD, MSCI, internationally respected leukemia researcher, Director of Leukemia Research for Sarah Cannon Research Institute and Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer of
Senti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell Segment
GlobeNewswire Inc.
Apr 16, 2025 1:15 PM GMT
Live moderated webcast with members of the Senti Bio management team on Wednesday, April 23rd at 4:00 PM ETSOUTH SAN FRANCISCO, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clin
Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.
GlobeNewswire Inc.
Apr 10, 2025 12:45 PM GMT
Industry leader in the development and application of cellular therapies, including CAR NK products, for cancer Led development of multiple clinical candidates from conception through IND and early clinical development Vast experience in technology